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A B S T R A C T
Susceptibility data for 10 049 Escherichia coli iso-
lates derived from community-acquired urinary
tract infections in Greece during the period January
2000 to June 2002 indicated 8.1% resistance to
nalidixic acid and 36% resistance to ciprofloxacin.
In a sample of 170 E. coli isolates, mutations in gyrA
(25 isolates) and parC (15 isolates) were consistent
with the levels of resistance to quinolones. Previous
exposure to quinolones and underlying chronic
disease were independent risk factors for infection
by quinolone-resistant E. coli strains.
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Intensive use of quinolones in the treatment of
common infections in humans and animals has
led to the spread of resistant microorganisms.
Quinolone resistance in Escherichia coli is mainly
caused by point mutations in the gyrA and parC
genes [1,2]. Such mutants are frequently encoun-
tered in hospitals worldwide. There are also
studies reporting the spread of quinolone-resist-
ant E. coli (QREC) strains in the community [3,4].
Susceptibility data from Greece have indicated a
relatively high incidence of quinolone resistance
among E. coli strains derived from hospital-
acquired urinary tract infections (UTIs) [5]. In
this study, the frequency of QREC isolates caus-
ing community-acquired UTIs in Greece was
estimated. The chromosomal mutations associ-
ated with quinolone resistance in a sample of such
isolates and the risk factors associated with
infection by QREC were also studied.
The frequency of QREC strains isolated from
community-acquired UTIs in 34 hospitals in
Greece during January 2000 to August 2002 was
calculated from the data collected by the National
Surveillance System for Antimicrobial Resistance
with the aid of WHONET software [6]. In order to
further study the epidemiological and biological
characteristics of resistance to quinolones, E. coli
strains were collected consecutively (March to
December 2000) from UTI outpatients at Laikon
teaching hospital in Athens. This is one of the
largest institutions participating in the National
Surveillance System for Antimicrobial Resistance,
with an active internal medicine outpatient clinic
serving a large catchment area that could be
considered representative of Athens. Patient data,
including demographics, underlying disease,
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immunological status, hospitalisations, invasive
device use, and use of antibiotics during the last
12 months, were also obtained. Patients admitted
to a hospital during the previous month were
excluded. Associations between QREC isolation
and various patient characteristics were assessed
by contingency tables and chi-square tests with
continuity corrections. Relative risks were estima-
ted by calculating odds ratios and their corres-
ponding 95% confidence intervals through
backward multiple logistic regression analysis
using Stata 6 software (StataCorp, College Station,
TX, USA).
Diagnosis of UTI was based on the presence of
at least one of the following criteria: urgency,
frequency, dysuria, or suprapubic tenderness and
the isolation of > 105 CFU ⁄mL of no more than
two species of microorganisms from urine. Iden-
tification of microorganisms was performed with
the API 20E System (bioMe´rieux, Marcy-l’Etoile,
France). MICs of nalidixic acid and ciprofloxacin
were determined by the Etest method (AB Bio-
disk, Solna, Sweden). Susceptibility to other anti-
microbials was determined according to the disk
diffusion breakpoints proposed by the National
Committee for Clinical Laboratory Standards
[7,8]. PCR-based typing of selected E. coli isolates
was carried out with ERIC2 primer (5¢-AA-
GTAAGTGACTGGGGTGAGCG) as described
previously [9]. Amplicons resulting from PCR
amplification of the quinolone resistance-deter-
mining regions of the gyrA and parC genes [2,10]
were purified with a QiaQuick spin PCR purifi-
cation kit (Qiagen, Hilden, Germany), and the
nucleotide sequences were determined with an
automatic sequencer (ABI Prism; Applied Biosys-
tems, Warrington, UK).
During January 2000 to June 2002, 10 049 E. coli
isolates were derived from community-acquired
UTIs in the 34 hospitals of the National Surveil-
lance System for Antimicrobial Resistance. Of the
10 049 isolates, 813 (8.1%) were resistant to nali-
dixic acid, and, of these, 366 (45.1%) were also
resistant to ciprofloxacin. Resistance to quinolones
was significantly associated with resistance to the
four non-quinolones routinely tested in all parti-
cipating hospitals (p < 0.01) (Table 1).
For further study, 170 E. coli isolates were
collected from UTI patients visiting the outpatient
clinic of the Laikon teaching hospital in Athens.
Of 25 (14.7%) nalidixic acid-resistant isolates,
15 (60%) were also resistant to ciprofloxacin.
Twenty-one (84%) QREC isolates were resistant
to ampicillin and 17 (68%) to co-trimoxazole
(Table 2), compared with 25% and 12.6%, respect-
ively, for quinolone-susceptible isolates. The
QREC isolates were also more frequently resistant
to gentamicin (28%) and tetracycline (68%) than
were the quinolonone-susceptible isolates (0.7%
and 17.4%, respectively). All of these differences
were statistically significant (p < 0.01).
Mutations in the quinolone resistance-deter-
mining region of the gyrA gene were detected in
all 25 nalidixic acid-resistant isolates. Additional
mutations in the quinolone resistance-determin-
ing region of the parC gene were found in 15 of
the QREC isolates. The most frequent mutations
were those resulting in the substitutions Leu
for Ser-83 of gyrA (22 isolates), Asn for Asp-87
of gyrA (15 isolates), and Ile for Ser-80 of parC
(14 isolates). High-level resistance to ciprofloxacin
was associated with mutations at both codons 83
and 87 of the gyrA gene and one or two additional
mutations in parC (codons 80 and 84) (Table 2).
ERIC2 PCR typing of the 25 QREC isolates
showed 14 distinct types, each represented by
between one and three isolates (data not shown).
The patient data did not indicate epidemiological
associations between these isolates.
Univariate analysis showed that isolation of
QREC strains was positively associated with age.
In comparison with younger patients, older
(‡ 65 years) UTI patients were at increased risk
of infection by a QREC strain than a quinolone-
susceptible strain (p ¼ 0.01). Isolation of QREC
strains was also strongly associated with the
presence of underlying chronic disease (p <
0.001), complicated UTIs (p ¼ 0.005), previous
UTI episodes (p < 0.001), and recent exposure to
quinolones (p < 0.001). There was no significant
association with gender or the use of non-
Table 1. Percentage frequencies of resistance to ciprofl-
oxacin and non-quinolone antibiotics among nalidixic
acid-susceptible (Na-S) and -resistant (Na-R) isolates
derived from outpatients during January 2000 to August







(n = 10 049)
Ciprofloxacin 0 45.1 3.6
Ampicillin 33.6 76.1 37.1
Co-trimoxazole 31.4 72.6 34.7
Gentamicin 5.4 17.4 6.4
Tetracycline 44.6 84.7 47.8
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quinolone antibiotics. Multivariate logistic regres-
sion analysis indicated that only chronic disease
(odds ratio 22.3; confidence interval 3–128;
p ¼ 0.03) and use of fluorinated quinolones (odds
ratio 80.7; confidence interval 11–613; p < 0.001)
were independent risk factors for infection by a
QREC strain in this population.
The surveillance data indicated a significant
rate of quinolone resistance among E. coli strains
from community-acquired UTIs throughout
Greece. Most of the QREC isolates examined in
this study carried multiple chromosomal muta-
tions known to confer resistance to quinolones.
These mutations were consistent with the
respective resistance levels to nalidixic acid and
ciprofloxacin, although the simultaneous pres-
ence of other resistance mechanisms cannot be
excluded.
The epidemiological and typing data indicat-
ed that such resistant strains probably emerge
independently, possibly following selection dur-
ing treatment with quinolones, or are acquired
from exogenous sources [3,11–13]. The former
possibility is supported by the strong associ-
ation with previous use of fluoroquinolones.
Indeed, all but two of the QREC isolates were
from patients with recent exposure to these
agents. Chronic disease also appeared to be an
independent risk factor, but this might be a
surrogate marker for antibiotic use before the
period covered by the study. Notably, most
QREC strains were also resistant to other drug
classes. Multiresistance may be an important
factor for the establishment of QREC strains in
chronically ill individuals requiring frequent
antimicrobial chemotherapy.
Table 2. Mutations in the quinolone resistance-determining regions and antibiotic resistance phenotypes of 25 QREC




gyrA parC MICs (mg ⁄L) Other resistance markers
Ser-83 Asp-87 Ser-80 Glu-84 Nal Cip Amp Sxt Gm Tet
1 Leu – – – 128 0.25 R R S R
2 Leu – – – 64 0.25 R R S S
3 Leu – – – 128 0.25 S S S R
4 Leu – – – 512 0.25 R R S R
5 Leu – – – 512 0.5 S S S R
6 Leu – – – 64 0.125 R R S R
7 Ile – – – 512 0.5 R R S S
8 – Gly – – 128 0.125 R S S S
9 – Tyr – – 64 0.125 S S S S
10 Leu Gly – – 512 1 S S S S
11 Leu Asn Ile – 512 64 R S R R
12 Leu Asn Ile – 512 8 R R S R
13 Leu Asn Ile – 512 64 R R S R
14 Leu Asn Ile – 512 16 R S R S
15 Leu Asn Ile – 512 16 R R R R
16 Leu Asn Ile – 512 8 R R R R
17 Leu Asn Ile – 512 64 R R S R
18 Leu Asn Ile – 512 16 R R S R
19 Leu Asn Ile – 512 64 R R R S
20 Leu Asn Ile – 512 64 R R S R
21 Leu Asn Ile – 512 64 R R S R
22 Leu Asn – Lys 512 8 R S S S
23 Leu Asn Ile Val 512 64 R R R R
24 Leu Asn Ile Gly 512 64 R R R R
25 Leu Asn Ile Lys 512 64 R R S R
S1a Ser Asp Ser Glu 4 0.032 R S S S
S2a Ser Asp Ser Glu 4 0.016 R S S S
aQuinolone-susceptible strains from the same setting.
Amp, ampicillin; Cip, ciprofloxacin; Gen, gentamicin; Nal, nalidixic acid; Sxt, co-trimoxazole; Tet, tetracycline.
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A B S T R A C T
Stock solutions of telithromycin, ABT-773, azith-
romycin, clarithromycin, erythromycin, roxithro-
mycin and dirithromycin were each prepared
with eight different combinations of solvents and
diluents. Broth microdilution trays were then
prepared and frozen at ) 60 C. Standard quality
control strains were evaluated periodically during
a 12-week storage time. There were no significant
changes in MICs with different solvents and
diluents. It was concluded that the easiest
approach was to dissolve each compound in
water with a small volume (< 2.5 lL ⁄mL) of
glacial acetic acid added in a dropwise fashion,
followed by further dilutions in deionised water.
Keywords Ketolide, macrolide, stock solu-
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As part of an effort to standardise antimicrobial
susceptibility testing procedures, the National
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